Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria Hemasphere
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms bioRxiv
Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients Haematologica
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO BRIT J HAEMATOL
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy TRANSPL CELL THER
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study HEMATOL ONCOL
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia BLOOD ADV
Correction to: High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion Cancer Gene Ther
FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma CANCER MED-US
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors FRONT IMMUNOL